{"database":"EGA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"dataset_type":["Illumina HiSeq 2000;"],"full_dataset_link":["https://ega-archive.org/datasets/EGAD00001000627"],"sample_count":["68"],"description":["EGA dataset EGAD00001000627"],"repository":["EGA"],"title":["RNA Editing Transcriptome"],"pubmed_abstract":["<h4>Background</h4>Microarrays have revolutionized breast cancer (BC) research by enabling studies of gene expression on a transcriptome-wide scale. Recently, RNA-Sequencing (RNA-Seq) has emerged as an alternative for precise readouts of the transcriptome. To date, no study has compared the ability of the two technologies to quantify clinically relevant individual genes and microarray-derived gene expression signatures (GES) in a set of BC samples encompassing the known molecular BC's subtypes. To accomplish this, the RNA from 57 BCs representing the four main molecular subtypes (triple negative, HER2 positive, luminal A, luminal B), was profiled with Affymetrix HG-U133 Plus 2.0 chips and sequenced using the Illumina HiSeq 2000 platform. The correlations of three clinically relevant BC genes, six molecular subtype classifiers, and a selection of 21 GES were evaluated.<h4>Results</h4>16,097 genes common to the two platforms were retained for downstream analysis. Gene-wise comparison of microarray and RNA-Seq data revealed that 52% had a Spearman's correlation coefficient greater than 0.7 with highly correlated genes displaying significantly higher expression levels. We found excellent correlation between microarray and RNA-Seq for the estrogen receptor (ER; rs = 0.973; 95% CI: 0.971-0.975), progesterone receptor (PgR; rs = 0.95; 0.947-0.954), and human epidermal growth factor receptor 2 (HER2; rs = 0.918; 0.912-0.923), while a few discordances between ER and PgR quantified by immunohistochemistry and RNA-Seq/microarray were observed. All the subtype classifiers evaluated agreed well (Cohen's kappa coefficients >0.8) and all the proliferation-based GES showed excellent Spearman correlations between microarray and RNA-Seq (all rs >0.965). Immune-, stroma- and pathway-based GES showed a lower correlation relative to prognostic signatures (all rs >0.6).<h4>Conclusions</h4>To our knowledge, this is the first study to report a systematic comparison of RNA-Seq to microarray for the evaluation of single genes and GES clinically relevant to BC. According to our results, the vast majority of single gene biomarkers and well-established GES can be reliably evaluated using the RNA-Seq technology."],"pubmed_title":["Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology."],"pubmed_authors":["Fumagalli Debora D, Blanchet-Cohen Alexis A, Brown David D, Desmedt Christine C, Gacquer David D, Michiels Stefan S, Rothé Françoise F, Majjaj Samira S, Salgado Roberto R, Larsimont Denis D, Ignatiadis Michail M, Maetens Marion M, Piccart Martine M, Detours Vincent V, Sotiriou Christos C, Haibe-Kains Benjamin B"],"name_synonyms":["Vasp, VASP, Data Set., DmelCG15112, ENHANCER OF ATNSI ACTIVITY, MENA, NDPP1, l(2)02029, Enb, enb, ENA, Ena, CG15112, ENA/VASP"],"pubmed_title_synonyms":["Breast Carcinoma, Human Mammary Neoplasm, primary breast cancer, Carcinoma, malignant tumor of the breast, RNA, Ribonucleic, Breast Carcinomas, \"breast neoplasm\" EXACT [MTH:120], ribose nucleic acid, Neoplasms, Arts, ribonucleic acids, mammary neoplasm, Gene, Mammary Cancers, Human Mammary Neoplasms, RNS, Tumor, \"breast tumor\" EXACT [NCI2004_11_17:C2910], Human, Breast Malignant Neoplasm, Breast Malignant Tumor, \"neoplasm of breast (disorder)\" EXACT [SNOMEDCT_2005_07_31:126926005], Mammary Carcinomas, Breast Tumor, yeast nucleic acid, Ribonukleinsaeure, Neoplasm, Gene Products, Human Mammary Carcinoma, \"mammary tumor\" EXACT [CSP2005:2016-0671], pentosenucleic acids, NOS, breast tumor, cancer of the breast, Ribonucleic acids, Malignant Neoplasm of Breast, Non Polyadenylated, RNA Gene Products, Carcinomas, BC, Mammary Neoplasms, malignant neoplasm of breast, ribonucleic acid, Acid, Human Mammary, Breast Neoplasm, Gene Expressions, Industrial Arts, Mammary Neoplasm, Non Polyadenylated RNA, Mammary Carcinoma, Human Mammary Carcinomas, Non-Polyadenylated, Cancers, Ribonucleic Acid, \"mammary neoplasm\" RELATED [], Expressions, Cancer of the Breast, Non-Polyadenylated RNA, breast cancer, cancer of breast, Malignant Tumor of Breast, Mammary, Mammary Cancer, Breast Tumors, Breast Cancer, Breast Malignant Tumors, microarray, Cancer of Breast, Expression, Industrial., Breast, mammary cancer, cancer, mammary tumor, Breast Malignant Neoplasms, breast, Tumors, Cancer"],"description_synonyms":["Transcriptome, Malignant Neoplasm, Malignancy, Transcriptome Profile, Profile, Neoplasms, average., Expression Profiles, Benign Neoplasm, Gene Expression Profile, Gene, Benign Neoplasms, Profiles, Cancers, Tumor, Malignant, Signatures, Malignant Neoplasms, Neoplasias, Gene Expression, Benign, Expression Signature, Gene Expression Profiles, Expression Signatures, Gene Expression Signatures, Transcriptomes, Neoplasm, Malignancies, Gene Expression Signature, Signature, other neoplasm, Expression Profile, Neoplasia, Transcriptome Profiles, Cancer, Tumors"],"pubmed_abstract_synonyms":["Erbb-2, Ribonucleic, ERBB2 Gene Amplification Negative, Materials, ectodin, CDH1 Wild-Type, Cytogenetically Normal, CEK Gene Mutation Negative, B.1.617.1 India December 2020, BCC7 Gene Mutation Negative, A2, ESTRB Negative, Estrogen Receptor Type II, ECT1 Gene Rearrangement Negative, Profiles, Tumor, TRT Promoter Mutation Negative, Alternative, GNA11 Gene Mutation Negative, Normal Tissue, SARS Coronavirus 2 Variant Lineage B.1.617.1, sequencing assay, Immunogold-Silver Techniques, Biological, Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Gene Amplification Negative, Summary Report, Accepted, Correlated, node-negative, BCS, correlation, BRAF Wildtype, H. pylori Negative, Laboratory Research, Non Polyadenylated, Hepatitis B Virus Core Antibody Negative, BC, SET, No rearrangement detected, HER2/neu Gene Mutation Negative, Gene Variation, Molecular, ESR Negative, FGFBR Gene Mutation Negative, plant peltate hair, KGFR Gene Mutation Negative, PDCD1L1 Negative, N, Tissue, BCs, MET Amplification Negative, HER2 Non-Amplified, PGR Negative, Based, DmelCG4299, ATRX Mutation Negative, XNP Gene Mutation Negative, isoform CRA_e, Immunogold-Silver Technic, FMS-Like Tyrosine Kinase 2 Gene Rearrangement Negative, PAX8 Gene Rearrangement Negative, HG-U133 Plus 2 array, FGFR1 Rearrangement Negative, Breast Malignant Neoplasms, Tumors, Organism by Subtype, Luminal A breast carcinoma, TP53 Gene Mutation Negative, Anti-HBc Negative, Serum CA 19-9 Normal, TP53 Mutation Negative, Research Priorities, BRAF wt, Normal skin, Normalcy, 1p/19q Co-deletion Negative, Human Immunodeficiency Virus Negative, TMEM16A Negative, Immunolabeling Technic, Marker, Expression Signatures, CTNNB1 Wildtype, Ribonucleic acids, Technics, LCAM Gene Mutation Negative, Flavoprotein Subunit of Complex II Negative, Expression Profile, Ret Proto-Oncogene Rearrangement Negative, FGFR3 Wild-Type, Luminal B, c-neu, Luminal A, Carcinomas, Research and Development, Estrogen Receptor Type I, GD - REM, Industrial Arts, DI-2, I-2Dm, Predominant, Immunogold Silver Techniques, Androgen Receptor Negative, Immunologic, \"mammary neoplasm\" RELATED [], B7-H Negative, Laboratory Marker, Present, c-KIT Negative, Activities, I-2PP1, p16INK4a Negative, Report, v-Ets Erythroblastosis Virus E26 Oncogene Like Gene Rearrangement Negative, ATRX Gene Mutation Negative, human epidermal growth factor receptor 2, Unmethylated O-6-Methylguanine-DNA Methyltransferase Gene Promoter, GT, EBV Negative, Breast Malignant Tumors, TRP53 Gene Mutation Negative, B7H1 Negative, cancer, Hepatitis B Core Antibody Negative, Immunogold-Silver, Estrogen Receptor, BJS, Neoplasms, peltate hair, HER-2 Gene Mutation Negative, B-RAF1 Gene Rearrangement Negative, Alpha Thalassemia/Mental Retardation Syndrome X-Linked Gene Mutation Negative, Mammary Cancers, Anti-HBc Antibody Negative, Succinate Dehydrogenase [Ubiquinone] Iron-Sulfur Subunit, SDHF Negative, Estrogen Nuclear Receptor, Breast Tumor, BRCA1 Associated Protein 1 Gene Mutation Negative, K-SAM Gene Mutation Negative, Gene Products, Nuclear Receptor Subfamily 3 Group A Member 2 Negative, N-SAM Gene Rearrangement Negative, NRAS Wildtype, HER-2/neu, CD333 Gene Mutation Negative, Expression Negative, KRAS Wildtype, GNA11 Wild-Type, Technique, ETV Rearrangement Negative, ESR1 Negative, c-MET Gene Amplification Negative, Cadherin-Associated Protein, In, B-RAF1 Gene Mutation Negative, MC3DN1, Clinical, Tissues, Estrogen Nuclear, Profile, FGFR1 Gene Mutation Negative, FGFR-2 Gene Mutation Negative, CDH1 Mutation Negative, xpr-2, 2pp2a, FGFR-2 Gene Rearrangement Negative, SDHA Negative, pgr, GD:REM, Sequencing, CG10574, KRAS2 Gene Mutation Negative, Abilities, Alpha 11 Gene Mutation Negative, Kappa, RAD54 Homolog Gene Mutation, Estrogen Receptor Alpha Negative, ETV Family Rearrangement Negative, GRACILE, FLT2 Gene Mutation Negative, dSet, Keratinocyte Growth Factor Receptor Gene Rearrangement Negative, ERBB2 wt, p53 Gene Mutation Negative, HBsAg Negative, Investigative Reports, JUAN DE NOVA ISLAND, NORMAL, Neu, Breast Carcinoma, Human Mammary Neoplasm, Hepatitis B Virus Surface Antibody Negative, SINGLE, Breast Carcinomas, Q Polypeptide Gene Mutation Negative, Fibroblast Growth Factor Receptor 1 Gene Rearrangement Negative, ETS Transcription Factor ERG Gene Rearrangement Negative, Harvey Rat Sarcoma Viral Oncogene Homolog Gene Mutation Negative, HER-2|neu, Serum Markers, SDHIP Negative, Guantanamo Bay Naval Base, Immunohistocytochemistry, FGFR2 Wild-Type, Progestin Receptor, Negative Number, isoform CRA_a, Immune Marker, Beta Catenin Gene Mutation Negative, del(10q23)/PTEN Gene Locus Deletion Negative, CTNNB1 Gene Mutation Negative, ATRX, MT, chemical analysis, Research Reports, TP53 wt, Alpha-11 Gene Mutation Negative, scales, Hepatitis B Surface Protein Antigen Negative, NEGATIVE, Quantify, Paired Domain Gene 8 Gene Rearrangement Negative, Single Person, BEK Gene Mutation Negative, Unmethylated MGMT Promoter, Organism Subtype, ensemble, c-erbB2, Ribonucleic Acid, Progestin Receptors, ERBB2 Wildtype, High, No, BPs, Lack of Expression of PD-L1, Catenin Beta 1 Gene Mutation Negative, Talent, GUANTANAMO BAY NAVAL BASE, Immunolabeling Techniques, Gene Mutation, Succinate Dehydrogenase [Ubiquinone] Flavoprotein Subunit, Main, stromal connective tissue, Anti-Hepatitis B Core Antibody Negative, HER-2 Positive, PR, malignant tumor of the breast, scale tissue, Derived, Biological Markers, Viral Marker, LFS1 Gene Mutation Negative, Normal Male External Genitalia, BAP1 Wildtype, Telomerase Reverse Transcriptase Gene Promoter Mutation Negative, selection process, Greater Than, Gene Expression Profile, Endpoint, Human Mammary Neoplasms, Estra, Human Herpesvirus-4 Negative, Technic, SUBTYPE, GDC Platform Terminology, QU, Techniques, Laboratory Markers, Immunogold-Silver Technique, Mathematical Derivation, ESR2 Negative, ORAOV2 Negative, HER2delta16 protein, gene expression, ATRX Wildtype, BRAF Mutation Negative, Mammary Neoplasms, ESR-Beta Negative, Luminal A subtype of breast carcinoma, Gene Expressions, TAF-I, CD274 Negative, Human Mammary Carcinomas, Keratinocyte Growth Factor Receptor Gene Mutation Negative, USAG-1, BAP1 wt, PAX8 Rearrangement Negative, IGAAD, How Often Felt Normal, Chromatin Remodeler Gene Mutation Negative, FGFR-1 Gene Rearrangement Negative, Immune, DmelCG10574, Had, Erb-B2 Receptor Tyrosine Kinase Gene Mutation Negative, Normal, None detected, BAP1 Wild-Type, ER-Alpha Negative, Has, None Detected, Gene Mutant, SDHB Loss, Ha-ras Gene Mutation Negative, GNA-11 Gene Mutation Negative, GNAQ Wildtype, \"breast neoplasm\" EXACT [MTH:120], HBsAb Negative, ribose nucleic acid, FGFR-1 Gene Mutation Negative, ribonucleic acids, StF-IT-1, Negative, Biochemical Markers, results, FLT-2 Gene Mutation Negative, BRAF Wild Type, Evaluation, Gene Expression, Ets Variant Gene Family Rearrangement Negative, ESRA Negative, FGFR3 Rearrangement Negative, KAL2 Gene Mutation Negative, ESTRR Negative, Malignant Neoplasm of Breast, Fibroblast Growth Factor Receptor 2 Gene Mutation Negative, FGFR2 Mutation Negative, p16INK4 Negative, Guanine Nucleotide Binding Protein (G Protein), Derivation, Nucleic Acid Sequencing, Quantitation, HHV-4 Negative, Relative Value, Prognostic, HRAS Gene Mutation Negative, Relevance, E-Cadherin Gene Mutation Negative, CG4299, estrogen receptor negative, Estrogen Receptors, 1p/19q Intact, HER2 Wildtype, MLN 19, Lowering, FLT-2 Gene Rearrangement Negative, Expressed, Biochemical Marker, Base, TKR1, Gene Variant, Tumor Protein p53 Gene Mutation Negative, Unmethylated MGMT Gene Promoter, i2pp2a, PR Negative, Estrogen Receptors Type I, primary breast cancer, Normal Chest Appearance, KAL2 Gene Rearrangement Negative, tissue, Clinical Markers, GAQ Gene Mutation Negative, NR3C3, Negative Finding, v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Negative, broad, Established, PHAPII, Surrogate End Points, JKT4 Gene Mutation Negative, Nucleic Acid Sequencing Technology Platform Name, Surrogate Markers, FGFR1 Wildtype, Neuroblastoma RAS Viral Oncogene Homolog Gene Mutation Negative, Evaluation Procedure, Investigative, OGD Gene Mutation Negative, RRG6, SDHB Deficient, Estrogen Receptors Type II, \"mammary tumor\" EXACT [CSP2005:2016-0671], GES, Anti-Hepatitis B Virus Surface Antibody Negative, c-K-ras Gene Mutation Negative, MET Proto-Oncogene, Mitochondrial Negative, study, Human Mammary, NR3A1 Negative, PRESENT, HHV4 Negative, Research, NRAS Wild-Type, GNA11 Wildtype, NR3A1, Biological Marker, ipp2a2, Normal Gait, G-ALPHA-q Gene Mutation Negative, PDL1 Negative, FGFR1 Gene Rearrangement Negative, Non-Polyadenylated RNA, CD331 Gene Mutation Negative, p16(INK4a) Negative, GEP6, Immunologic Markers, Erg-3 Gene Rearrangement Negative, Mammary, Mammary Cancer, Found, Normal Abdomen on Visual Inspection, N-RAS Gene Mutation Negative, Breast, Immunologic Marker, Possess, KGFR Gene Rearrangement Negative, CD332 Gene Rearrangement Negative, Juan de Nova Island, GENETIC_SEQ, Succinate Dehydrogenase Complex Flavoprotein Subunit A Negative, Transcriptome, FLG Gene Rearrangement Negative, Beta Gene Mutation Negative, FGFR3 Gene Mutation Negative, More Than, igaad, FGFR1 Mutation Negative, Normal Precordial Palpation Finding, XJN, group, Luminal B estrogen receptor positive subtype of breast carcinoma, Anti-HBs Antibody Negative, Breast Malignant Neoplasm, Priority, DRVFL, GNA11 wt, Research Activities, I2PP2A, XKM, 9930019P03Rik, Lowered, Anoctamin-1 Negative, Breast Neoplasm, Serum Marker, ER Beta Negative, HER2/Neu Positive, UVO Gene Mutation Negative, ERBB2 Mutation Negative, Normality, FGFR3 wt, Non Polyadenylated RNA, Succinate Dehydrogenase Complex Iron Sulfur Subunit B Negative, Non-Polyadenylated, Talents, KIT Negative, ERA Negative, OGD Gene Rearrangement Negative, B-RAF Gene Mutation Negative, CTNNB1 wt, Calcium-Dependent Adhesion Protein, Absent, introduction, Alternate, SDH1 Negative, dSET/TAF-Ibeta, NEU Gene Amplification Negative, 2610030F17Rik, alternative, GTPase Gene Mutation Negative, CD324 Gene Mutation Negative, B7 Homolog 1 Negative, Only, Breast Cancer, Estr, IDH wt Allele, BAP1 Gene Mutation Negative, Single, Summary, Field Report, Surrogate Endpoints, Laboratory, CDKN2A-p16(INK4a) Negative, Cyclin-Dependent Kinase 4 Inhibitor A Negative, FLNMS, Hepatitis B Surface Antigen Negative, Receptors, Hs.6719, Progress Reports, Nuclear Receptor, 912, GNAQ Gene Mutation Negative, CDH1 Wildtype, UCHL2 Gene Mutation Negative, HiSeq 2000, 918, 5730420M11Rik, Relative, Compared, Kiaa3023, Nuclear Receptor Subfamily 3 Group A Member 1 Negative, GNAQ Mutation Negative, Progesterone Receptor Negative, FGFR-3 Gene Mutation Negative, H-ras Gene Mutation Negative, Normal Appearance of the Extremities, C-HA-RAS1 Gene Mutation Negative, cancer of the breast, CDKN2A-p16 Negative, Research Activity, ENSMUSG00000074510, 923, v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Rearrangement Negative, Priorities, HER-2 protein, average, Correlation, HRas Proto-Oncogene, Loss of Expression, BFGFR Gene Rearrangement Negative, Luminal B breast cancer, Progress Report, B.1.617.1, HBcAb Negative, Comparison, Isocitrate Dehydrogenase (NADP+) Gene Family Wildtype, Cytogenetic Abnormalities Absent, IP Negative, Normality-Based Dosing Unit, Signatures, Normal Capillary Refill Time, epidermal growth factor receptor 2, set, Anti-HBsAb Negative, Field Reports, cancer of breast, Expression Signature, Familiar, Receptor Tyrosine Kinase Gene Amplification Negative, Immunolabeling Technique, Catenin Beta-1 Gene Mutation Negative, Negative Charge, HER2 protein, REM, HBs Antigen Negative, FGFR-3 Gene Rearrangement Negative, ER Alpha Negative, 0610006G05Rik, ERB Negative, SARS2 B.1.617.1, h-BCS, ERBB2 Wild-Type, FGFR1 wt, sequencing_assay, CDH1 Gene Mutation Negative, Viral, Aptitudes, Immunogold Technique, MT (more than), Derived Flag, MLN19, GNA11 Mutation Negative, Evaluated, CD117 Negative, Cadherin, Immunolabeling Technics, Helicobacter pylori Negative, Arc-1 Gene Mutation Negative, Acid, HLA-DR-associated protein II, End Points, Epstein Barr Virus Negative, Affymetrix HT Human Genome U133 Plus 2 Array Plate Set, EST2 Promoter Mutation Negative, HGFR Gene Amplification Negative, Guanine Nucleotide-Binding Protein, HRAS Mutation Negative, v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Gene Amplification Negative, Field, Relation, INSDC_feature:gene, Beta-Catenin Gene Mutation Negative, EGFR2 protein, ATRX wt, human, Anti-Hepatitis B Virus Core Antibody Negative, HBs Negative, TERT Promoter Mutation Negative, ERG Gene Rearrangement Negative, TAF-IBETA, breast cancer, Material, GNAQ wt, Proliferation, CDHE Gene Mutation Negative, Breast Tumors, Wise, CTNNB Gene Mutation Negative, MET Gene Amplification Negative, TAF-Ibeta, Progestin, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 protein, KRAS Gene Mutation Negative, GENC Entity 4, BRAF Gene Mutation Negative, Epstein-Barr Virus Negative, c-Met Amplification Negative, HER2 Gene Mutation Negative, G Protein Subunit Alpha q Gene Mutation Negative, Not Expressed, Clinical Marker, Luminal A oestrogen receptor positive subtype of breast carcinoma, Negative Estrogen Receptor, HER2 wt, Human, ER-, Breast Malignant Tumor, Altretamine/Cisplatin/Cyclophosphamide/Misonidazole, Biopolymer Sequencing, Sequencing Platform Name, CMC1 Gene Mutation Negative, FGFBR Gene Rearrangement Negative, Li-Fraumeni Syndrome Gene Mutation Negative, breast tumor, IDH Family Gene Mutation Negative, NRAS Gene Mutation Negative, Higher, Immunogold Silver Technics, Negative Lymph Node, Normalities, Normal Skin, Neu protein, FGFR3 Mutation Negative, Mammary Neoplasm, proliferating, Mammary Carcinoma, JKT4 Gene Rearrangement Negative, ZNF-HX Gene Mutation Negative, GA11 Gene Mutation Negative, Ets Variant Family Rearrangement Negative, Paired Box Gene 8 Gene Rearrangement Negative, Expressions, PDCD1LG1 Negative, NEU Gene Mutation Negative, ESR, 2PP2A, del10q23/Phosphatase and Tensin Homolog Gene Locus Negative, Malignant Tumor of Breast, CTNNB1 Wild-Type, dSET, NEG, ER-Beta Negative, Development and Research, Expression, BRCA1-Associated Protein 1 Gene Mutation Negative, Programmed Cell Death 1 Ligand 1 Negative, BFGFR Gene Mutation Negative, Progesterone Receptors, Biologic, Cancer, NEU, TCS1 Promoter Mutation Negative, HER2/neu Gene Amplification Negative, RNA, Epithelial Gene Mutation Negative, FGFR3 Wildtype, Immunogold Technic, RNS, CTNNB1 Mutation Negative, \"breast tumor\" EXACT [NCI2004_11_17:C2910], Hepatocyte Growth Factor Receptor Gene Amplification Negative, HG-U133 Plus 2, Affymetrix, TERT Gene Promoter Mutation Negative, Have, I-2PP2A, Surrogate End Point, Gene Expression Signatures, Dm I-2, Neoplasm, KRAS Wild-Type, Human Mammary Carcinoma, NGL, ATRX Wild-Type, CD333 Gene Rearrangement Negative, background, KIT Proto-Oncogene Tyrosine Protein Kinase Negative, Relevant, ESRB Negative, B-RAF Gene Rearrangement Negative, Immunolabeling, Biologic Markers, RET Rearrangement Negative, BRAF Rearrangement Negative, IDH Mutation Negative, Erb-B2 Receptor Tyrosine Kinase Gene Amplification Negative, Immunocytochemistry, Evaluate, Estrogen, p16 Negative, Surrogate, PD-L1 Negative, HER2 Gene Amplification Negative, Endpoints, Fibroblast Growth Factor Receptor 1 Gene Mutation Negative, Cancers, Normal Appearance of Extremities, Normal Capillary Refill, RAD54L Gene Mutation Negative, Derived Value, Fibroblast Growth Factor Receptor 3 Gene Rearrangement Negative, Reports, IDP Gene Mutation Negative, Gene Expression Profiles, NRAS Mutation Negative, CDH1 wt, ETV Family Gene Rearrangement Negative, ANO1 Negative, Immunogold-Silver Technics, Cancer of Breast, Solitary, FGFR1 Wild-Type, Receptor, Industrial., p16-INK4 Negative, Progesterone, breast, CEK Gene Rearrangement Negative, Alone, Immune Markers, IPP2A2, Activity, determination, SWS Gene Mutation Negative, G Protein Subunit Alpha 11 Gene Mutation Negative, PLATFORM, ER Negative, Biochemical, mammary neoplasm, Serum, Highly, BRAF Gene Rearrangement Negative, BCS1, CD340, \"neoplasm of breast (disorder)\" EXACT [SNOMEDCT_2005_07_31:126926005], FLG Gene Mutation Negative, HRAS Wild-Type, Human Herpesvirus 4 Negative, BAP1 Mutation Negative, Summary Reports, RNA Gene Products, malignant neoplasm of breast, CD332 Gene Mutation Negative, No mutation detected, Observed, p55 Gene Rearrangement Negative, Cyclin-Dependent Kinase Inhibitor 2A Negative, Progesterone receptor, CD331 Gene Rearrangement Negative, CHIPS, Progress, Markers, PR-, TP53 Wildtype, Viral Markers, ENTITY 4, FGFR2 Gene Rearrangement Negative, Estrogen Receptor 2 Negative, FGFR2 Gene Mutation Negative, Transcriptomes, DERIVED, Progesterone Receptor, BB114106, Research Priority, mammary cancer, CD274 Molecule Negative, Immunogold Technics, SDH2 Negative, SARS Coronavirus 2 B.1.617.1, v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog Gene Mutation Negative, Normal Thoracic Appearance, negative test result, phapii, Platform Version, Lower, Carcinoma, FMS-Like Tyrosine Kinase 2 Gene Mutation Negative, Estrogen Receptor 1 Negative, wide/broad, Surrogate Endpoint, XH2 Gene Mutation Negative, CDDP/CTX/HMM/MNI, Arts, Expression Profiles, Paired Box 8 Gene Rearrangement Negative, Hepatitis B Surface Antibody Negative, Technology Platform Version, Normal Reference Range, RNA-seq, Luminal B oestrogen receptor positive subtype of breast carcinoma, Biologic Marker, NR3A2 Negative, Ability, Immunogold, Immunogold Techniques, HRAS wt, Investigative Report, Ribonukleinsaeure, pentosenucleic acids, Genetic Materials, NOS, HER2 Positive, Estrogen Receptor Negative, LOWER, Genetic Material, Normal Immune Presence, Subtype, ETV Gene Rearrangement Negative, Transcriptome Profiles, PTD, IDH Gene Family Wildtype, Epistemology, HER-2 Gene Amplification Negative, ERBB2 Gene Mutation Negative, RASH1 Gene Mutation Negative, IDH Gene Mutation Negative, Isocitrate Dehydrogenase Gene Family Wild Type, GNAQ Wild-Type, 10q23/PTEN Locus Deletion Negative, common, BEK Gene Rearrangement Negative, Presence, AX2, wide, ECAD Gene Mutation Negative, Health, Sostl, DOG1 Negative, v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Gene Mutation Negative, FGFR2 Wildtype, microarray, Cistron, Hepatitis B Virus Surface Antigen Negative, Sequence Analysis, Proliferating, Quantification, Platform, LOST, v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Gene Mutation Negative, Transcriptome Profile, Technology Platform, Correlative, PR-B, IDH Family Wildtype, PR-A, Gene, Compare, ECT1 Gene Mutation Negative, Anti-HBcAb Negative, FGFR2 wt, SEQUENCING, FLT2 Gene Rearrangement Negative, CD274 Antigen Negative, HRAS Wildtype, Whole Transcriptome Shotgun Sequencing, Fp Negative, Negative Test Result, Anti-HBs Negative, Type I, FGFR3 Gene Rearrangement Negative, N-SAM Gene Mutation Negative, Biomarker, SDHB Deficiency, Genetic, 1p/19q Codeletion Negative, HER-2, Mast/Stem Cell Growth Factor Receptor Kit Negative, RELATIVE, RAD54 Gene Mutation Negative, Cancer of the Breast, ERBB2 Positive, Luminal A estrogen receptor positive subtype of breast carcinoma, TISSUE, taf-ibeta, Luminal A breast cancer, Luminal B subtype of breast carcinoma, Known, mammary tumor, Cadherin 1 Gene Mutation Negative, v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Mutation Negative, AR Negative, XPR-1, Molecular Biology, RET Gene Rearrangement Negative, HIV Negative, NRAS wt, KRAS-2 Gene Mutation Negative, del(1p/19q) Negative, mKIAA3023, Excellent, End Point, FGFR2 Rearrangement Negative, ERBB2 Non-Amplified, Fibroblast Growth Factor Receptor 3 Gene Mutation Negative, Cistrons, KRAS wt, TP2 Promoter Mutation Negative, IDH Wild Type, Mammary Carcinomas, Normal Point of Maximum Impulse, yeast nucleic acid, HER2 Wild-Type, Fibroblast Growth Factor Receptor 2 Gene Rearrangement Negative, Gene Expression Signature, ERG Rearrangement Negative, K-SAM Gene Rearrangement Negative, Basic, ribonucleic acid, progesterone receptor negative, scale, MGMT Gene Promoter Methylation Negative, platform, Basis, Unit of Concentration, RET/PTC Rearrangement Negative, Unmethylated Methylguanine-DNA Methyltransferase Gene Promoter, No abnormality detected, Surrogate Marker, NUCLEIC ACID SEQUENCING, Estrogen Receptor Beta Negative, DER, SDHB Negative, assay, Signature, Type II, AA407739, HER2, TAOS2 Negative, Luminal B breast carcinoma"],"additional_accession":[]},"is_claimable":false,"name":"ena-DATASET-BCTL-03-07-2013-15:15:20:064-67 - samples","description":"Transcriptome sequencing data of tumor and 10 matched normal samples of the EGAS00001000495 project","dates":{"updated":"2017-07-26 15:39:25"},"accession":"EGAD00001000627","cross_references":{"TAXONOMY":["9606"],"pubmed":["25412710"],"EGA":["EGAC00001000120","EGAS00001000495"]}}